ACE and metabolic syndrome: In subgroup analyses, increased risk for ESKD in VIM quartile 4 versus quartile 1–3 was more evident in individuals aged 40–64 years, with a prescription history of ACE inhibitors or ARBs, hypertension, and dyslipidemia (Table 3).